{"entity":{"id":"locametz","kind":"drug","name":"Locametz (kit for Ga-68 gozetotide)","aka":[],"tldr":"Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.","summary":"Locametz was approved by the FDA on 23 March 2022, alongside Pluvicto (lutetium-177 vipivotide tetraxetan), with an explicit indication for selecting patients with metastatic castration-resistant prostate cancer for PSMA-directed therapy, as well as for initial staging and biochemical recurrence. The European Commission approved it in December 2022. It is manufactured by Advanced Accelerator Applications, the Novartis radiopharmaceutical unit, and was the first PSMA PET agent approved in the EU. The scan-then-treat pairing is the template for theranostics.","status":"approved","asOf":"2026-09-10","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Locametz"}],"tags":["test"],"related":["ga68-psma-11","illuccix"],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","pet-ct","radioligand-therapy"],"targets":["psma"],"drugs":["pluvicto"],"companies":["novartis","advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":["theranostics"],"trials":["vision"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["What a result means: enough PSMA uptake on the scan is required before Pluvicto can be given; a scan without uptake means the drug is unlikely to work."],"brand":"Locametz","modality":"PET imaging agent kit (PSMA, gallium-68)","mechanism":"Kit for on-site labelling of gozetotide (PSMA-11) with gallium-68; the resulting tracer images PSMA-expressing prostate cancer and identifies candidates for lutetium-177 PSMA therapy.","approvals":[{"region":"US","year":2022,"indication":"PSMA PET in prostate cancer, including selection of patients for PSMA radioligand therapy"},{"region":"EU","year":2022,"indication":"PSMA PET in prostate cancer"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/locametz/","neighbours":{"drug":[{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/"},{"id":"illuccix","kind":"drug","name":"Illuccix (kit for Ga-68 gozetotide)","route":"/drugs/illuccix/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"term":[{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/"}],"trial":[{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/"}],"biomarker":[{"id":"psma-pet-expression","kind":"biomarker","name":"PSMA expression by PET (PSMA-positive)","route":"/biomarkers/psma-pet-expression/"}]}}